학술논문
The Use of 2 ndGeneration TKIs As First Line Therapy Does Not Prevent CML Related Deaths: Results of an Italian CML Campus Prospective Study in 1277 Patients Treated First Line with Imatinib or 2 ndGeneration TKIs
Document Type
Article
Author
Giai, Valentina; Stagno, Fabio; Rosso, Tiziana; Castagnetti, Fausto; Capodanno, Isabella; Bonifacio, Massimiliano; Tiribelli, Mario; Galimberti, Sara; Bocchia, Monica; Gozzini, Antonella; Caocci, Giovanni; Patriarca, Andrea; Lanzarone, Giuseppe; Guella, Anna; Sorà, Federica; Luciano, Luigiana; Scortechini, Anna Rita; Di Renzo, Nicola; Musto, Pellegrino; Pastore, Domenico; Maggi, Alessandro; Fava, Carmen; Pavone, Vincenzo; Fozza, Claudio; Spinosa, Giuseppina; Carella, Angelo Michele; Tarantini, Giuseppe; Martino, Bruno; Pizzuti, Michele; Mannarella, Clara; Saccona, Fabio; Rosti, Gianantonio; Pregno, Patrizia; Breccia, Massimo; Pane, Fabrizio; Ciccone, Giovannino; Specchia, Giorgina; Saglio, Giuseppe
Source
Blood; November 2023, Vol. 142 Issue: 1, Number 1 Supplement 1 p3168-3168, 1p
Subject
Language
ISSN
00064971; 15280020
Abstract
Background: In the last decades prognosis and survival of chronic myeloid leukemia (CML) patients have dramatically improved, thanks to a wider therapeutic armamentarium. Molecular responses are the milestones that guide clinical decisions; however, some information is still lacking and what we know derives mainly from investigational trials: it is still unclear if real-life management could lead to comparable results. For this reason, a prospective observational study was conducted by a CML Italian network to analyze molecular responses in a real-life setting.